Skip to main content
    S

    Stoke Therapeutics Inc (STOK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $26.63
    -0.05 (-0.19%)

    Market Cap: $1.75B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Stoke Therapeutics Inc (STOK) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    Stoke Therapeutics reported revenue of $184.42M for the fiscal year ended Dec 31, 2025, up 404.5% from the year before. That year, net income was -$6.88M with a net margin of -3.7%, operating cash flow was $45.59M and free cash flow was $44.91M. The quarter ended Sep 30, 2026 had revenue of $11.26M and net income of -$73.64M.

    Revenue and Margins

    The operating margin was -11.2% in the fiscal year ended Dec 2025.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$184.42M+404.5%100.0%-11.2%-3.7%
    Dec 2024$36.55M+316.3%100.0%-277.3%-243.4%
    Dec 2023$8.78M-29.2%100.0%-1307.2%-1192.5%
    Dec 2022$12.40MN/A100.0%-841.2%-814.7%
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$184.42M$36.55M$8.78M$12.40M$0$0$0$0$0
    Cost of revenue$0$0$0$0$0$0$0$0$113.00K
    Gross profit$184.42M$36.55M$8.78M$12.40M$0$0$0$0-$113.00K
    Research and development$137.92M$89.13M$82.23M$77.84M$54.17M$32.20M$23.76M$8.37M$3.60M
    Operating income-$20.59M-$101.37M-$114.77M-$104.36M-$86.06M-$53.04M-$35.68M-$12.78M-$5.55M
    Net income-$6.88M-$88.98M-$104.70M-$101.07M-$85.81M-$52.24M-$32.33M-$12.52M-$5.56M
    EBITDA-$20.00M-$101.08M-$112.46M-$102.85M-$84.81M-$52.05M-$35.23M-$12.58M-$5.44M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$11.26M$9.32M$6.23M$1.40M$10.63M$13.82M$158.57M$22.61M$4.89M$4.83M$4.22M$2.80M
    Gross profit$11.26M$9.32M$6.23M$1.40M$10.63M$13.82M$158.57M$22.61M$4.89M$4.83M$4.22M$2.80M
    Operating income-$77.31M-$65.43M-$53.42M-$61.44M-$43.09M-$27.30M$111.24M-$13.65M-$30.00M-$29.34M-$28.37M-$29.59M
    Net income-$73.64M-$61.62M-$50.00M-$57.93M-$38.35M-$23.48M$112.88M-$10.48M-$26.43M-$25.70M-$26.37M-$26.96M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $3.01M by $81.21M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$418.43M$271.56M$228.34M$256.07M$238.87M$297.93M$228.75M$107.54M$2.44M
    Current assets$305.70M$232.76M$215.34M$244.07M$229.22M$293.93M$226.03M$106.14M$1.91M
    Cash and equivalents$84.22M$127.98M$191.44M$113.56M$144.90M$287.31M$222.47M$105.40M$1.80M
    Total liabilities$65.98M$42.53M$68.78M$71.22M$21.09M$11.85M$4.32M$2.47M$3.73M
    Short-term debt$3.01M$2.32M$2.06M$2.36M$1.51M$1.07MN/A$0$3.00M
    Shareholder equity$352.46M$229.02M$159.56M$184.85M$217.78M$286.08M$224.43M$105.07M-$1.29M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$406.69M$393.97M$443.28M$418.43M$360.26M$384.51M$406.89M$271.56M$293.32M$307.76M$205.18M$228.34M
    Total liabilities$54.10M$48.42M$48.40M$65.98M$52.16M$49.56M$56.81M$42.53M$61.21M$65.05M$64.84M$68.78M
    Cash and equivalents$107.27M$110.00M$155.66M$84.22M$83.39M$101.47M$274.82M$127.98M$150.02M$193.48M$178.58M$191.44M
    Shareholder equity$352.59M$345.55M$394.88M$352.46M$308.11M$334.94M$350.07M$229.02M$232.11M$242.71M$140.34M$159.56M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 98.5% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow$45.59M-$86.85M-$81.07M-$31.87M-$66.91M-$42.22M-$31.05M-$10.96M-$5.38M
    Capital expenditures$670.00K$203.00K$1.62M$3.96M$1.20M$1.05M$1.64M$935.00K$113.00K
    Free cash flow$44.91M-$87.05M-$82.68M-$35.83M-$68.11M-$43.27M-$32.69M-$11.90M-$5.50M
    Share repurchasesN/AN/AN/AN/AN/A$306.00K$2.46M$378.00KN/A
    Investing cash flow-$186.81M-$107.47M$105.95M-$45.88M-$76.43M-$1.05M-$1.63M-$925.00K-$113.00K
    Financing cash flow$97.39M$131.09M$53.01M$46.41M$1.28M$108.11M$149.76M$115.64M$5.97M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$62.69M-$56.59M-$60.58M-$30.45M-$30.37M-$25.42M$131.83M-$23.19M-$21.61M-$17.48M-$24.57M-$20.65M
    Capital expenditures$2.85M$1.98M$353.00K$232.00K$132.00K$154.00K$152.00K$42.00K$103.00K$46.00K$12.00K$229.00K
    Free cash flow-$65.54M-$58.56M-$60.94M-$30.69M-$30.50M-$25.58M$131.68M-$23.23M-$21.72M-$17.52M-$24.58M-$20.88M
    Last 12 quarters

    Frequently Asked Questions About STOK

    What is Stoke Therapeutics' annual revenue?

    Stoke Therapeutics reported revenue of $184.42M for the fiscal year ended Dec 31, 2025.

    How fast is Stoke Therapeutics' revenue growing?

    Revenue was up 404.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 145.9%.

    Is Stoke Therapeutics profitable?

    No. Stoke Therapeutics reported net income of -$6.88M for the fiscal year ended Dec 31, 2025, with a net margin of -3.7%.

    How much free cash flow does STOK generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $45.59M minus capital expenditures of $670.00K produced free cash flow of $44.91M.

    How much debt does Stoke Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $3.01M and cash and equivalents of $84.22M.